NVS

Today, 9:35 AMNovartis beats Q2 2026 estimates with non-GAAP EPS $2.41, revenue $14.4B and core operating income $5.94B vs $5.31B expected

Peers: LLY AZN MRK ABBV JNJ PFE BMY GSK SNY AMGN

| Held by: DFIV DFIC DFAI AVDE PPH DIHP DFAX FVD LCAP FENI

Scroll to Statements

Index	-
Market Cap	282.79B
Enterprise Value	323.23B
Income	13.60B
Sales	54.66B
Book/sh	20.18
Cash/sh	3.81
Dividend Est.	4.44 (2.88%)
Dividend TTM	4.74 (3.07%)
Dividend Ex-Date	Mar 11, 2026
Dividend Gr. 3/5Y	10.71% 8.17%
Payout	42.50%
Employees	75267
IPO	Nov 07, 1996

P/E	22.02
Forward P/E	15.91
PEG	2.59
P/S	5.17
P/B	7.65
P/C	40.53
P/FCF	16.03
EV/EBITDA	15.10
EV/Sales	5.91
Quick Ratio	0.65
Current Ratio	0.85
Debt/Eq	1.22
LT Debt/Eq	1.02
Option/Short	Yes / Yes

EPS (ttm)	7.02
EPS next Y	9.71
EPS next Q	2.26
EPS this Y	-3.06%
EPS next Y	11.56%
EPS next 5Y	6.15%
EPS past 3/5Y	31.40% 15.38%
Sales past 3/5Y	9.03% 2.41%
EPS Y/Y TTM	9.68%
Sales Y/Y TTM	5.60%
EPS Q/Q	-9.32%
Sales Q/Q	-0.59%
Earnings	Jul 21 BMO
EPS/Sales Surpr.	10.95% 2.43%

Insider Own	0.01%
Insider Trans	0.00%
Inst Own	7.92%
Inst Trans	-3.81%
ROA	12.45%
ROE	35.38%
ROIC	17.52%
Gross Margin	74.58%
Oper. Margin	29.69%
Profit Margin	24.89%
SMA20	0.09%
SMA50	2.15%
SMA200	6.36%
Trades

Shs Outstand	1.91B
Shs Float	1.83B
Short Float	0.29%
Short Ratio	2.98
Short Interest	5.36M
52W High	170.46 -9.37%
52W Low	112.34 37.52%
Volatility	1.79% 1.57%
ATR (14)	3.23
RSI (14)	53.01
Beta	0.47
Rel Volume	1.70
Avg Volume	1.79M
Volume	1,702,261

Perf Week	2.74%
Perf Month	5.03%
Perf Quarter	2.31%
Perf Half Y	7.03%
Perf YTD	12.05%
Perf Year	35.35%
Perf 3Y	55.47%
Perf 5Y	80.43%
Perf 10Y	120.29%
Recom	2.57
Target Price	153.06
Prev Close	149.56
Price	154.49
Change	3.29%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Upgrade	Argus	Hold → Buy	$180
Jan-27-26	Initiated	Citigroup	Buy
Jan-06-26	Upgrade	Barclays	Underweight → Equal Weight
Dec-08-25	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-25-25	Upgrade	BofA Securities	Neutral → Buy
Sep-12-25	Downgrade	Goldman	Neutral → Sell	$118
Aug-08-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$123
Feb-13-25	Downgrade	UBS	Buy → Neutral
Feb-12-25	Initiated	Morgan Stanley	Underweight
Feb-04-25	Upgrade	Deutsche Bank	Hold → Buy
Dec-04-24	Downgrade	HSBC Securities	Hold → Reduce
Sep-11-24	Downgrade	BofA Securities	Buy → Neutral	$135 → $130
Sep-05-24	Downgrade	Goldman	Buy → Neutral
Sep-03-24	Downgrade	Jefferies	Buy → Hold
Jul-19-24	Downgrade	Deutsche Bank	Buy → Hold
May-30-24	Initiated	Goldman	Buy	$120
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy

Show Previous Ratings

Today 09:24AM	Novartis Q2 2026 earnings beat as cancer, MS drugs drive growth (Quartz)
09:22AM	U.S. stocks set for higher open as strong earnings boost market sentiment: Dow Jones, S&P, Nasdaq, Wall Street Futures (InvestorsHub)
08:15AM	Novartis Earnings Beat, Cash Flow Weakens (GuruFocus.com)
07:31AM	Novartis Q2 profits recover as revenue mantle passes to newer medicines (Pharmaceutical Technology)
06:53AM	Novartis returns to sales growth in Q2 as newer medicines offset generic pressure (NVS) (InvestorsHub)
02:58AM	Loading…
02:58AM	Novartis says buoyed by new treatments in second quarter (AFP)
01:51AM	Novartis: Q2 Earnings Snapshot (Associated Press)
Jul-20-26 11:15AM	Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks? (FX Empire)
09:16AM	Earnings To Watch: Novartis AG (XSWX:NOVN) Reports Q2 2026 Result (GuruFocus.com)
06:05AM	Novartis pipeline faces critical test as upcoming trial results underpin growth outlook (InvestorsHub)
04:54AM	Bristol Myers to build powerful AI factory; Samsung Biologics bids for peptide maker (BioPharma Dive)
Jul-17-26 07:36AM	FDA grants traditional approval to Novartis' Fabhalta for IgAN (Pharmaceutical Business Review)
Jul-16-26 08:05AM	Why Abbott Earnings Are Sending the Stock Higher (Barrons.com)
Jul-14-26 06:14AM	Novartis and Chai Discovery collaborate on antibody identification (Pharmaceutical Business Review)
Jul-09-26 07:03AM	This Analyst Sees 34% Upside For SRPT Stock Here's Why They Expect A Sustained Rally Next (Stocktwits)
12:38PM	Loading…
Jul-07-26 12:38PM	Novartis Buys Myricx Bio in $1.5 Billion Deal (GuruFocus.com)
Jul-06-26 11:30AM	Novartis is buying a U.K. cancer drug startup for up to $1.5 billion (Quartz)
11:29AM	Novartis acquires U.K. cancer biotech Myricx Bio for $1.5 billion (Quartz)
09:47AM	Novartis Buys Myricx Bio in Up to $1.5 Billion Cancer Drug Deal (GuruFocus.com)
07:05AM	Novartis to acquire Myricx Bio in up to $1.5bn deal (Pharmaceutical Business Review)
Jul-03-26 06:05AM	European Commission approves Novartis' Itvisma to treat SMA (Pharmaceutical Business Review)
Jun-25-26 03:53PM	Candel Therapeutics Designates Mark Sims as CCO (Exec Edge)
09:34AM	Novartis Eyes $5 Billion Pluvicto Opportunity (GuruFocus.com)
06:10AM	Antares gets $105M from Novartis for new cancer drugs (BioPharma Dive)
Jun-24-26 01:47PM	Novartis Targets Hard-to-Treat Cancers (GuruFocus.com)
10:12AM	Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal (Pharmaceutical Technology)
Jun-23-26 08:20AM	Should You Buy Or Sell AbbVie Stock At $230? (Trefis)
Jun-21-26 01:21AM	Swiss voters likely to reject stricter neutrality proposal, poll shows (Investing.com)
Jun-19-26 05:13AM	ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain (Pharmaceutical Technology)
Jun-17-26 12:39PM	Vedana debuts with $46m to progress migraine therapies (Pharmaceutical Technology)
07:40AM	Loading…
Jun-11-26 07:40AM	Novartis $12bn bet on Avidity well placed after mid-stage FSHD win (Clinical Trials Arena)
06:18AM	Novartis RNA drug acquired in $12B Avidity deal notches a trial win (BioPharma Dive)
Jun-09-26 05:19PM	FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge)
11:05AM	Applied Digital inks hyperscaler deal, Vail Resorts cuts guidance (Yahoo Finance Video)
07:56AM	GSK doubles down on oncology with $10.6bn Nuvalent takeover (Pharmaceutical Technology)
Jun-03-26 07:57AM	Legend surges on early data for in vivo lymphoma cell therapy (BioPharma Dive)
Jun-02-26 11:28AM	ASCO 2026: Mixed SCLC result for Legends LB2102, Novartis expedites manufacture (Pharmaceutical Technology)
May-21-26 06:42AM	Podcast: Supply chains, obesity drugs, and patents dominate Q1 earnings trends (Medical Device Network)
May-20-26 11:01AM	BioArctic AB (BRCTF) Q1 2026 Earnings Call Highlights: Strong Sales and Strategic Partnerships ... (GuruFocus.com)
May-12-26 07:42AM	Pharmas manufacturing reconfigurations provide CDMOs with expansion opportunities (Pharmaceutical Technology)
May-08-26 07:05AM	Construction begins on Novartis' RLT centre in Texas, US (Pharmaceutical Business Review)
May-07-26 02:46PM	DARZALEX royalties drive Genmabs Q1 revenue higher amid expansion push (Investing.com)
May-06-26 11:40AM	European Bond Market Has Record Day as Rates Outlook Worsens (Bloomberg)
May-04-26 08:23AM	Celcuity strengthens case for ASCO-spotlighted breast cancer drug (BioPharma Dive)
Apr-29-26 01:09PM	Novartis Expands R&D Spending Up To $70 Million Monthly After Avidity Deal (GuruFocus.com)
07:18AM	Novartis Q1 sales miss hints at industrys utilisation of M&A remedies (Pharmaceutical Technology)
03:03AM	Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income ... (GuruFocus.com)
Apr-28-26 02:14PM	Novartis CEO warns of reality of Trump's drug pricing policy (CNBC TV)
08:31AM	Novartis misses in Q1 but sticks with full-year outlook (GuruFocus.com)
02:03AM	Novartis: Q1 Earnings Snapshot (Associated Press)
Apr-27-26 09:15AM	Novartis AG (XSWX:NOVN) Q1 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:40AM	Novartis secures pair of regulatory wins for skin disease and malaria treatments (Pharmaceutical Business Review)
Apr-24-26 10:45AM	Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings (Pharmaceutical Technology)
07:17AM	Novartis Secures Positive EU Backing for SMA Gene Therapy Itvisma (InvestorsHub)
Apr-21-26 10:04AM	This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. (Barrons.com)
Apr-14-26 11:48AM	Anthropic adds Novartis CEO Vas Narasimhan to its board (Reuters)
Apr-02-26 09:25AM	Lilly Pushes Back on Making Drug Price Deals Permanent (GuruFocus.com)
Mar-31-26 03:45PM	$2 Billion Bayer Verdict: What the Roundup Decision Means for MAHA (Exec Edge)
03:51AM	Big Pharma goes nuts over food allergies again (Pharma Voice)
Mar-30-26 09:17AM	Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises. (Barrons.com)
Mar-29-26 06:26AM	Swiss-U.S. trade talks to blow past March deadline amid tariff uncertainty (Investing.com)
Mar-27-26 12:14PM	Novartis Agrees Up to $2B Excellergy Deal Amid Generic Pressure (GuruFocus.com)
10:29AM	Novartis Expands Pipeline With $2 Billion Biotech Deal (GuruFocus.com)
10:24AM	Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy (Proactive)
07:41AM	Novartis to acquire Excellergy for $2bn upfront (Pharmaceutical Business Review)
07:22AM	Novartis targets Xolair successor in buyout of startup Excellergy (BioPharma Dive)
03:50AM	Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion (Reuters)
Mar-26-26 08:10AM	Mercks deal for Terns sparks debate over a possible biotech bidding war (BioPharma Dive)
Mar-25-26 11:49AM	MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement (Pharmaceutical Technology)
Mar-24-26 07:03PM	Tesla, SMCI, Others See Sharp Analyst Revisions (GuruFocus.com)
Mar-20-26 02:09PM	Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal (GuruFocus.com)
08:25AM	Novartis Places $3 Billion Bet On Early Cancer Drug (GuruFocus.com)
07:23AM	Novartis to acquire SNV4818 from Synnovation (Pharmaceutical Business Review)
06:34AM	Novartis pays $2B to land a startups breast cancer drug (BioPharma Dive)
Mar-19-26 04:00AM	Novartis acquisition spin-off pioneers RNA therapeutics for the heart (Pharma Voice)
Mar-18-26 02:29PM	Analysis-TrumpRx lists many medicines at prices higher than paid in UK (Reuters)
Mar-17-26 08:09AM	Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal (GuruFocus.com)
Mar-16-26 01:33PM	Julius Baers $30 Million Pay Package Shows the Price of a Banking Reset (Moby)
06:50AM	Novartis wins FDA approval for Cosentyx to treat paediatric HS patients (Pharmaceutical Business Review)
Mar-10-26 12:14PM	VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study (Zacks)
Mar-09-26 12:22PM	Why Is Olema Pharmaceuticals Stock Dropping On Monday? (Benzinga)
12:11PM	INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz (Zacks)
Mar-08-26 04:49PM	These 8 drugs could help fight dementia - and they're already on the market (MarketWatch)
Mar-06-26 05:55AM	Novartis, Nucor partner US Forged Rings and others expand domestic investments (Manufacturing Dive)
Mar-04-26 02:00AM	What This Top International ETF Is Buying Now (Barrons.com)
Mar-03-26 08:02PM	Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference (MarketBeat)
07:49PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
10:50AM	Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU (Zacks)
09:20AM	Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study (Zacks)
Mar-02-26 06:44PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
08:23AM	As Investors Flee U.S. Equities, This Global ETF Is Outperforming (MarketBeat)
Feb-28-26 02:41PM	Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement (Benzinga)
02:21AM	Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas (Insider Monkey)
Feb-27-26 07:58AM	Atrium spins out of Avidity, aiming to target rare heart diseases with RNA (BioPharma Dive)
Feb-26-26 03:42PM	Generate caps a strong month for biotech IPOs with $400M offering (BioPharma Dive)
04:39AM	Boehringer drug approved in 44 days; BioMarin shelves Roctavian (BioPharma Dive)
Feb-25-26 02:32PM	Analyst Report: Alcon Inc. (Morningstar Research)
01:20PM	Analyst Report: Haleon plc (Morningstar Research)
07:45AM	Novartis to build radioligand therapy site in Texas to expand US manufacturing (Reuters)
07:15AM	Slate Medicines raises $130m in funds to progress anti-PACAP treatments (Pharmaceutical Technology)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Chief Executive OfficerDr. Vasant Narasimhan M.D.

President of USMr. Victor Bulto

President of InternationalDr. Patrick Horber M.D.

Chief Financial OfficerMr. Mukul Mehta

President of OperationsDr. Steffen Lang Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Bulto Carulla Victor	Officer	Apr 30 '26	Proposed Sale	148.10	6,800	1,007,093	Apr 30 12:05 PM
Marshall Fiona	Officer	Feb 12 '26	Proposed Sale	161.35	30,743	4,960,277	Feb 12 02:43 PM
Bulto Carulla Victor	Officer	Feb 09 '26	Proposed Sale	156.21	7,500	1,171,576	Feb 09 11:49 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novartis AG ADR

Upgrade your Finviz experience